PROHIBITED LIST INTERNATIONAL STANDARD
The official text of the Prohibited List shall be maintained by WADA and shall
be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail.
This List shall come into effect on 1 January 2011 IDSF Anti-Doping Code 2011 THE 2011 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 January 2011
All Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2.1 to S2.5, S.4.4 and S6.a, and Prohibited Methods M1, M2 and M3.
SUBSTANCES AND METHODS PROHIBITED AT ALL (IN- AND OUT-OF-COMPETITION)
S0. NON-APPROVED SUBSTANCES
Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (i.e. drugs
under pre-clinical or clinical development or discontinued) is prohibited at all times.
PROHIBITED SUBSTANCES
* “exogenous” refers to a substance which is not ordinarily capable of being produced by the body naturally.
** “endogenous” refers to a substance which is capable of being produced by the body naturally. S1. ANABOLIC AGENTS
Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS)
hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metenolone; methandienone (17β-hydroxy-17α-
methylandrosta-1,4-dien-3-one); methandriol; methasterone (2α, 17α- dimethyl-5α-androstane-3-one-17β-ol); methyldienolone (17β-hydroxy-17α- methylestra-4,9-dien-3-one);methyl-1-testosterone (17β-hydroxy-17α- methyl-5α-androst-1-en-3-one); methylnortestosterone (17β-hydroxy-17α- methylestr-4-en-3-one); methyltestosterone; metribolone (methyltrienolone, 17β-hydroxy-17α-methylestra-4,9,11-trien-3-one); mibolerone; nandrolone; 19-norandrostenedione (estr-4-ene-3,17- dione); norboletone; norclostebol; norethandrolone; oxabolone; oxandrolone; oxymesterone; oxymetholone; prostanozol (17β-hydroxy- 5α-androstano[3,2-c] pyrazole); quinbolone; stanozolol; stenbolone; 1- testosterone (17β-hydroxy-5α-androst-1-en-3-one); tetrahydrogestrinone
(18a-homo-pregna-4,9,11-trien-17β-ol-3-one); trenbolone; and other substances with a similar chemical structure or similar biological effect(s).
b. Endogenous** AAS when administered exogenously: androstenediol (androst-5-ene-3β,17β-diol); androstenedione (androst-4- ene-3,17-dione); dihydrotestosterone (17β-hydroxy-5α-androstan-3-one); prasterone (dehydroepiandrosterone, DHEA); testosterone and the following metabolites and isomers:
2. Other Anabolic Agents, including but not limited to: Clenbuterol, selective androgen receptor modulators (SARMs), tibolone, zeranol, zilpaterol.
For purposes of this section:
* “exogenous” refers to a substance which is not ordinarily capable of being produced by the body naturally.
** “endogenous” refers to a substance which is capable of being produced by the body naturally.IDSF Anti-Doping Code 2011
S2. PEPTIDE HORMONES, GROWTH FACTORS AND RELATED SUBSTANCES The following substances and their releasing factors are prohibited:
3. Insulins; 4. Corticotrophins; 5. Growth Hormone (GH), Insulin-like Growth Factor-1 (IGF-1), Fibroblast Growth Factors (FGFs), Hepatocyte Growth Factor (HGF), Mechano Growth Factors (MGFs), Platelet-Derived Growth Factor (PDGF), Vascular-Endothelial Growth Factor (VEGF) as well as any other growth factor affecting muscle, tendon or ligament protein
synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching; and other substances with similar chemical structure or similar biological effect(s).
S3. BETA-2 AGONISTS
All beta-2 agonists (including both optical isomers where relevant) are prohibited except salbutamol (maximum 1600 micrograms over 24 hours) and salmeterol when taken by inhalation in accordance with the manufacturers’ recommended therapeutic regime.
The presence of salbutamol in urine in excess of 1000 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of a therapeutic dose (maximum 1600 micrograms over 24 hours) of inhaled salbutamol.
IDSF Anti-Doping Code 2011
S4. HORMONE ANTAGONISTS AND MODULATORS
The following classes are prohibited:
1. Aromatase inhibitors including, but not limited to: aminoglutethimide, anastrozole, androsta-1,4,6-triene-3,17-dione (androstatrienedione), 4-androstene-3,6,17 trione (6-oxo), exemestane, formestane, letrozole, testolactone. 2. Selective estrogen receptor modulators (SERMs) including, but not limited to: raloxifene, tamoxifen, toremifene.
3. Other anti-estrogenic substances including, but not limited to: clomiphene, cyclofenil, fulvestrant. 4. Agents modifying myostatin function(s) including, but not limited, to: myostatin inhibitors.
S5. DIURETICS AND OTHER MASKING AGENTS Masking agents are prohibited. They include: Diuretics, desmopressin, plasma expanders (e.g. glycerol; intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol), probenecid; and other substances with similar biological effect(s).
Diuretics include: Acetazolamide, amiloride, bumetanide, canrenone, chlorthalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone, thiazides (e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide), triamterene; and other substances with a similar chemical structure or similar biological effect(s) (except drosperinone, pamabrom and topical dorzolamide and brinzolamide, which are not prohibited).
The use In- and Out-of-Competition, as applicable, of any quantity of a substance subject to threshold limits (i.e. salbutamol, morphine, cathine, ephedrine, methylephedrine and pseudoephedrine) in conjunction with a diuretic or other masking agent requires the deliverance of a specific
Therapeutic Use Exemption for that substance in addition to the one granted for the diuretic or other masking agent.
IDSF Anti-Doping Code 2011
PROHIBITED METHODS
M1. ENHANCEMENT OF OXYGEN TRANSFER
The following are prohibited: 1. Blood doping, including the use of autologous, homologous or heterologous
blood or red blood cell products of any origin. 2. Artificially enhancing the uptake, transport or delivery of oxygen, including, but not limited to, perfluorochemicals, efaproxiral (RSR13) and modified haemoglobin products (e.g. haemoglobin-based blood substitutes, microencapsulated haemoglobin products), excluding supplemental oxygen.
M2. CHEMICAL AND PHYSICAL MANIPULATION
1. Tampering, or attempting to tamper, in order to alter the integrity and
validity of Samples collected during Doping Control is prohibited. These include but are not limited to catheterisation, urine substitution and/or adulteration (e.g. proteases). 2. Intravenous infusions are prohibited except for those legitimately received
in the course of hospital admissions or clinical investigations. 3. Sequential withdrawal, manipulation and reinfusion of whole blood into the circulatory system is prohibited.
M3. GENE DOPING The following, with the potential to enhance sport performance, are prohibited: 1. The transfer of nucleic acids or nucleic acid sequences;
2. The use of normal or genetically modified cells; 3. The use of agents that directly or indirectly affect functions known to influence performance by altering gene expression. For example, Peroxisome
Proliferator Activated Receptor δ (PPARδ) agonists (e.g. GW 1516) and PPARδ-AMP-activated protein kinase (AMPK) axis agonists (e.g. AICAR) are prohibited.
IDSF Anti-Doping Code 2011
SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION
In addition to the categories S0 to S5 and M1 to M3 defined above, the following categories are prohibited In-Competition: PROHIBITED SUBSTANCES
S6. STIMULANTS
All stimulants (including both optical isomers where relevant) are prohibited, except imidazole derivatives for topical use and those stimulants included in
the 2010 Monitoring Program*. Stimulants include: a: Non-Specified Stimulants:
Adrafinil; amfepramone; amiphenazole; amphetamine; amphetaminil; benfluorex; benzphetamine; benzylpiperazine; bromantan; clobenzorex; cocaine; cropropamide; crotetamide; dimethylamphetamine; etilamphetamine; famprofazone; fencamine; fenetylline; fenfluramine; fenproporex; furfenorex; mefenorex; mephentermine; mesocarb; methamphetamine(d-); p-methylamphetamine; methylenedioxyamphetamine; methylenedioxymethamphetamine; modafinil; norfenfluramine; phendimetrazine; phenmetrazine; phentermine; 4-phenylpiracetam (carphedon); prenylamine; prolintane.
A stimulant not expressly listed in this section is a Specified Substance. b: Specified Stimulants (examples): Adrenaline**; cathine***; ephedrine****; etamivan; etilefrine; fenbutrazate; fencamfamin; heptaminol; isometheptene; levmetamfetamine; meclofenoxate; methylephedrine****; methylhexaneamine (dimethylpentylamine); methylphenidate; nikethamide; norfenefrine; octopamine; oxilofrine; parahydroxyamphetamine; pemoline; pentetrazol; phenpromethamine; propylhexedrine; pseudoephedrine*****; selegiline; sibutramine; strychnine; tuaminoheptane; and other substances with a similar
chemical structure or similar biological effect(s). * The following substances included in the 2011 Monitoring Program (bupropion, caffeine, phenylephrine, phenylpropanolamine, pipradol, synephrine) are not considered as Prohibited Substances. ** Adrenaline associated with local anaesthetic agents or by local administration (e.g. nasal, ophthalmologic) is not prohibited. *** Cathine is prohibited when its concentration in urine is greater than 5 micrograms per milliliter. **** Each of ephedrine and methylephedrine is prohibited when its
concentration in urine is greater than 10 micrograms per milliliter. ***** Pseudoephedrine is prohibited when its concentration in urine is greater than 150 micrograms per milliliter. IDSF Anti-Doping Code 2011
S7. NARCOTICS
Buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its derivatives, hydromorphone, methadone, morphine, oxycodone, oxymorphone, pentazocine, pethidine. S8. CANNABINOIDS Natural (e.g. cannabis, hashish, marijuana) or synthetic delta 9- tetrahydrocannabinol (THC) and cannabimimetics [e.g. “Spice” (containing JWH018, JWH073), HU-210] are prohibited.
S9. GLUCOCORTICOSTEROIDS
All glucocorticosteroids are prohibited when administered by oral, intravenous, intramuscular or rectal routes.
IDSF Anti-Doping Code 2011
SUBSTANCES PROHIBITED IN PARTICULAR SPORTS
P1. ALCOHOL Alcohol (ethanol) is prohibited In-Competition only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold (haematological values) is 0.10 g/L. • Aeronautic (FAI)
• Archery (FITA) • Automobile (FIA) • DanceSport (IDSF) • Karate (WKF) • Motorcycling (FIM)
• Ninepin and Tenpin Bowling (FIQ) • Powerboating (UIM)
P2. BETA-BLOCKERS
Unless otherwise specified, beta-blockers are prohibited In-Competition only, in the following sports. • Aeronautic (FAI) • Archery (FITA) (also prohibited Out-of-Competition) • Automobile (FIA)
• Billiards and Snooker (WCBS) • Bobsleigh and Skeleton (FIBT) • Boules (CMSB) • Bridge (FMB) • Curling (WCF)
• DanceSport (IDSF) • Darts (WDF) • Golf (IGF) • Motorcycling (FIM) • Modern Pentathlon (UIPM) for disciplines involving shooting
• Ninepin and Tenpin Bowling (FIQ) • Powerboating (UIM) • Sailing (ISAF) for match race helms only • Shooting (ISSF, IPC) (also prohibited Out-of-Competition) • Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and
snowboard halfpipe/big air • Wrestling (FILA) Beta-blockers include, but are not limited to, the following: Acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol, carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol. IDSF Anti-Doping Code 2011
Metformin 2 Tage präop. absetzen, am OP-Tag kein Insulin und keine an- deren Antidiabetika 1 PRÄOPERATIV Sonstige Dauermedikation fortsetzen bis zum Tag vor OP, ggf. Rücksprache mit Stationsarzt und/oder Anästhesist 1 a OP-Indikation: 1 d Visite Klärung im kardiochirurgischen-kardiologischen KolloquiumUnterrichtung des Patienten über den Ablauf und die Vorbereitungen, Be- 1 b
Health & Permission Form Dargaville Primary School STUDENTS NAME …………………………………………. ROOM……………. EDUCATION OUTSIDE THE CLASSROOM Parents/Caregivers permission and medical information form I give permission for my son/daughter…………………………………………………. To participate in class camp/trip at ……
PROHIBITED LIST